| 2017 | EARLY PREDICTION OF THE MOLECULAR RESPONSE TO BCR-ABL1 TYROSINE KINASE INHIBITORS IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA | 문영철 | Meeting Abstract |
| 2017 | BORTEZOMIB-MELPHALAN-PREDNISONE VERSUS MP AS INITIAL TREATMENT FOR VERY ELDERLY PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA | 문영철 | Meeting Abstract |
| 2017 | COMPARISON OF MOLECULAR KINETICS AFTER THE FIRST AND SECOND IMATINIB DISCONTINUATION: RESULTS FROM THE KID STUDY | 문영철 | Meeting Abstract |
| 2017 | PEROXIREDOXIN II ACTIVITY HAS IMPORTANT ROLES TO CONTROL ABL TYROSINE KINASE ACTIVITY IN STIS TREATED CML PATIENTS AND ITS POTENTIAL APPLICATION IN IMATINIB RESISTANCE | 문영철 | Meeting Abstract |
| 2017 | VARIABLE NATURAL KILLER CELL ACTIVITY IN HEMATOLOGIC MALIGNANCIES AT DIAGNOSIS | 성주명; 허정원; 문영철 | Meeting Abstract |
| 2015 | INTERNATIONAL EXTRANODAL NK/T-CELL LYMPHOMA PROJECT: PROGNOSTIC FACTORS IN THE ERA OF NONANTHRACYCLINE-BASED TREATMENT | 문영철 | Meeting Abstract |
| 2015 | PREDICTIVE FACTORS FOR TREATMENT-FREE REMISSION IN CHRONIC MYELOID LEUKEMIA PATIENTS WITH IMATINIB-TREATED, UNDETECTABLE MOLECULAR RESIDUAL DISEASE: RESULTS FROM THE KID STUDY | 문영철 | Meeting Abstract |
| 2015 | MUTATION ANALYSIS OF JAK2, MPL, CALR, ASXL1, TET2, IDH1, IDH2, DNMT3A, AND SF3B1 IN MYELOPROLIFERATIVE NEOPLASM | 문영철 | Meeting Abstract |
| 2015 | CLINICOPATHOLOGIC CHARACTERISTICS OF UNCLASSIFIABLE MYELOPROLIFERATIVE NEOPLASMS | 문영철 | Meeting Abstract |
| 2004 | Establishment of effective B lymphocyte ex vivo expansion on human cord blood using TPO, SCF, FL, IL-4, IL-10, and CD40L. | 이순남; 성주명; 이경은; 문영철 | Meeting Abstract |
